CpG ODN 10101  (Synonyms: ODN 10101)

CpG ODN 10101 (ODN 10101; CPG 10101) is a selective agonist targeting TLR9, a synthetic oligodeoxynucleotide modified with phosphate thioester. CpG ODN 10101 activates B cells and plasmacytoid dendritic cells (pDCs), inducing the production of cytokines and chemokines such as interferon-IFN-α, interferon-inducible protein IP-10, and 2'5'-oligoadenylate synthase (2'5'-OAS), regulating innate immunity and promoting Th1 adaptive immune responses. CpG ODN 10101 also possesses antiviral properties and enhances vaccine immunogenicity, making it suitable as an immunomodulator and vaccine adjuvant for vaccine development in chronic hepatitis C and infectious diseases such as melioidosis, pertussis, and respiratory syncytial virus (RSV)^[1][2][3][4].

CpG ODN 10101 (10 μg/well; 48 hours) stimulates mouse J774 macrophages, and the MP complex formulation induced significantly higher levels of TNF-α, IL-6, and IL-12p40 than the soluble formulation (SOL) and the formulation without PCEP (AQ), while the SOL formulation induced the highest level of MCP-1^[3].
CpG ODN 10101 (10 μg/well, combined with 10 μg or 20 μg/well IDR 1002 and 10 μg/well PCEP; 48 hours) stimulates mouse J774 macrophages, and the cytokine levels induced by the uncomplexed MP formulations (MP-IDR + MP-CpG) were lower than those induced by the MP complex formulation^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

CpG ODN 10101 (75 μg/mouse; intranasal injection; single dose) in a melioidosis model of BALB/c mice prolonged mouse survival time, reduced bacterial load in the lungs, and induced early expression of cytokines such as TNF-α, IL-6, and MCP-1 in lung tissue^[2].
CpG ODN 10101 (10 μg/mouse, combined with 10 μg PCEP and 20 μg IDR 1002; subcutaneous injection; single dose) induced a strong Th1-type immune response in a pertussis model in BALB/c mice, increasing the number of IL-17-secreting cells in the spleen, increasing levels of MCP-1, TNF-α, and IFN-γ in lung tissue, decreasing IL-10 levels, and reducing the bacterial load of Bordetella pertussis in the lungs^[3].
CpG ODN 10101 (10 μg/mouse, combined with 10 μg PCEP, 20 μg IDR 1002, and 1 μg RSV F protein; intramuscular/intranasal injection; two doses) induced serum and lung tissue virus-neutralizing antibodies in an RSV infection model in BALB/c mice, increased IFN-γ-secreting cells, completely inhibited RSV replication in lung tissue, and caused no immunopathological damage^[4].
CpG ODN 10101 (10 μg/mouse, combined with 10 μg PCEP, 20 μg IDR 1002, and 1 μg RSV F protein; intramuscular injection; two doses) induced high levels of virus-neutralizing antibodies in an RSV infection model in cotton rats (Sigmodon hispidus), completely inhibited RSV replication in lung tissue, and reduced pulmonary inflammatory infiltration and alveolar septal thickening^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

6702.37

1234402-77-7

Solid

White to off-white

DNA, d(P-thio)(T-C-G-T-C-G-T-T-T-T-C-G-C-G-C-G-C-G-C-C-G)

[CpG ODN 10101]

Room temperature in continental US; may vary elsewhere.

-20°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

• [1]. McHutchison JG, et al. Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus. Hepatology. 2007 Nov;46(5):1341-9.  [Content Brief]

  [2]. Easton A, et al. Combining vaccination and postexposure CpG therapy provides optimal protection against lethal sepsis in a biodefense model of human melioidosis. J Infect Dis. 2011 Aug 15;204(4):636-44.  [Content Brief]

  [3]. Garlapati S, et al. Immunization with PCEP microparticles containing pertussis toxoid, CpG ODN and a synthetic innate defense regulator peptide induces protective immunity against pertussis. Vaccine. 2011 Sep 2;29(38):6540-8.  [Content Brief]

  [4]. Garlapati S, et al. Enhanced immune responses and protection by vaccination with respiratory syncytial virus fusion protein formulated with CpG oligodeoxynucleotide and innate defense regulator peptide in polyphosphazene microparticles. Vaccine. 2012 Jul 27;30(35):5206-14.  [Content Brief]